Eskopeo Advisors

𝗧𝗵𝗲𝗿𝗲 𝗶𝘀 𝗮 𝗴𝗮𝗽 𝗯𝗲𝘁𝘄𝗲𝗲𝗻 𝘆𝗼𝘂𝗿 𝗛𝗖𝗣 𝗦𝗧𝗥𝗔𝗧𝗘𝗚𝗬 𝗮𝗻𝗱 𝘆𝗼𝘂𝗿 𝗖𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗘𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲 𝗥𝗘𝗔𝗟𝗜𝗧𝗬 Why would Eskopeo Advisors, an advisory firm of former senior pharma executives, partner with msg industry advisors ag, a specialized life sciences consulting and transformation partner? Because we refuse to sell our clients a strategy that gets stuck in the code. Let’s talk about a silent EBIT drain in Commercial Excellence: the "𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝘃𝘀. 𝗥𝗲𝗮𝗹𝗶𝘁𝘆 𝗴𝗮𝗽"... You can design a brilliant, agile Go-to-Market (GTM) strategy at the board level. But if your sales reps are hitting the pavement with legacy target lists, duplicated databases, or outdated physician (HCP) master data, your strategy is flying blind. ➡️ Your reps waste time chasing “targeting ghosts.” ➡️ Your marketing automation triggers compliance risks. ➡️ Your commercial transformation stalls. ➡️ And margin is lost. Together, we bridge the gap between high-level commercial steering and the operational foundation needed to execute it – across data, CRM, processes, governance and compliant system enablement. 🎯 𝗦𝘆𝘀𝘁𝗲𝗺 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗼𝗻 𝘁𝗵𝗮𝘁 𝗘𝗺𝗽𝗼𝘄𝗲𝗿𝘀 𝘁𝗵𝗲 𝗙𝗶𝗲𝗹𝗱 Eskopeo identifies hidden champions in the portfolio, locates high-potential territories, and redesigns sales force models to capture margin. msg industry advisors translates this commercial ambition into scalable operating models, reliable HCP/HCO data structures, CRM capabilities and process designs that make those targets actionable on the ground. ⚙️ 𝗚𝘅𝗣-𝗖𝗼𝗺𝗽𝗹𝗶𝗮𝗻𝘁 𝗖𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗘𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲 Together, we simplify commercial processes and reduce database complexity before backend customization starts. This ensures physician and HCP data remains high-quality, compliant, actionable, and fit for commercial use – without unnecessary overengineering. 𝗜𝗳 𝘆𝗼𝘂𝗿 𝗱𝗮𝘁𝗮 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝗵𝗶𝘁𝘀 𝗿𝗼𝗮𝗱𝗯𝗹𝗼𝗰𝗸𝘀, 𝘆𝗼𝘂𝗿 𝗲𝘅𝗲𝗰𝘂𝘁𝗶𝗼𝗻 𝗶𝘀 𝗰𝗼𝗺𝗽𝗿𝗼𝗺𝗶𝘀𝗲𝗱. Our integrated alliance ensures that commercial strategy translates into clear processes, reliable data, compliant systems and measurable business outcomes. 👉 Contact us to receive our joint executive brief. 📩 info@eskopeo.com #CommercialExcellence #HCPEngagement #CRM #MasterDataGovernance #PharmaTransformation

𝗘𝘀𝗸𝗼𝗽𝗲𝗼 𝗔𝗱𝘃𝗶𝘀𝗼𝗿𝘀 𝘂𝗻𝗱 𝗜𝗻𝘀𝗶𝗴𝗵𝘁 𝗛𝗲𝗮𝗹𝘁𝗵 𝗚𝗺𝗯𝗛 ü𝗯𝗲𝗿𝘀𝗲𝘁𝘇𝗲𝗻 𝗴𝗲𝗺𝗲𝗶𝗻𝘀𝗮𝗺 𝗠𝗮𝗿𝗸𝘁𝗶𝗻𝘁𝗲𝗹𝗹𝗶𝗴𝗲𝗻𝘇 𝗶𝗻 𝗲𝗳𝗳𝗲𝗸𝘁𝗶𝘃𝗲 𝗚𝗼-𝘁𝗼-𝗠𝗮𝗿𝗸𝗲𝘁 𝗠𝗼𝗱𝗲𝗹𝗹𝗲   In der hart umkämpften DACH-Pharmalandschaft stehen wir als ehemalige Betreiber und Führungskräfte oft vor denselben harten Fragen:   ➡️ 𝗪𝗲𝗹𝗰𝗵𝗲 𝗣𝗿𝗼𝗱𝘂𝗸𝘁𝗲 im Portfolio haben echtes, profitables Wachstumspotenzial? ➡️ 𝗪𝗲𝗹𝗰𝗵𝗲 𝗡𝗶𝘀𝗰𝗵𝗲𝗻-𝗣𝗿ä𝗽𝗮𝗿𝗮𝘁𝗲 sind unsere unentdeckten Ertragsbringer („Hidden Champions“)? ➡️ 𝗪𝗼 𝘃𝗲𝗿𝗯𝗿𝗲𝗻𝗻𝗲𝗻 𝘄𝗶𝗿 𝘄𝗲𝗿𝘁𝘃𝗼𝗹𝗹𝗲 𝗥𝗲𝘀𝘀𝗼𝘂𝗿𝗰𝗲𝗻 an unrentablen Produkten oder veralteten Strukturen?   Die bittere Realität: Viele Go-to-Market-Modelle basieren auf veralteten Annahmen, während teuer lizenzierte Marktdaten ungenutzt in Silos liegen.   Genau hier setzt unsere Allianz mit Insight Health GmbH an. Wir verbinden lückenlose Datenintegrität mit kompromissloser C-Level-Execution. So kombinieren wir valide Marktdaten mit strategischer Beratung zu einem durchgängigen Entscheidungs-Framework für das Top-Management von Pharmaunternehmen:   📈 Insight Health GmbH liefert das Fundament (𝗱𝗶𝗲 𝗙𝗮𝗸𝘁𝗲𝗻): Als Goldstandard für Marktdaten im deutschen Gesundheitswesen liefert Insight Health hochgranulare Einblicke – von GKV-Rezeptdaten über Apotheken- und Arzt-Panels bis hin zu regionalen Dynamiken und Verschreibungstrends. ⚙️ Eskopeo Advisors liefert die Übersetzung (𝗱𝗶𝗲 𝗘𝘅𝗲𝗰𝘂𝘁𝗶𝗼𝗻): Wir übersetzen diese Markttransparenz direkt in messbare EBIT-Steigerungen. Wir bereinigen Portfolios, eliminieren Komplexität und strukturieren GTM- und Außendienstmodelle so um, dass Ihre Teams genau dort agieren, wo der maximale Ertrag liegt.   𝗪𝗮𝘀 𝗯𝗲𝗱𝗲𝘂𝘁𝗲𝘁 𝗱𝗮𝘀 𝗸𝗼𝗻𝗸𝗿𝗲𝘁? 1️⃣ 𝗞𝗲𝗶𝗻𝗲 𝗔𝗻𝗻𝗮𝗵𝗺𝗲𝗻 𝗺𝗲𝗵𝗿: Ihre strategische Roadmap steht auf einem evidenzbasierten Fundament. 2️⃣ 𝗙𝗼𝗸𝘂𝘀 𝘀𝘁𝗮𝘁𝘁 𝗩𝗲𝗿𝘇𝗲𝘁𝘁𝗲𝗹𝘂𝗻𝗴: Radikale Portfolio-Diagnostik zur schnellen Freisetzung von Working Capital und Fokussierung auf die Hebel, die wirklich zur Wertsteigerung beitragen.   Wenn Sie wissen wollen, wie wir gemeinsam Ihre Daten in echte Wertsteigerung übersetzen, lassen Sie uns ins Gespräch kommen! 🤝   #CommercialExcellence #PortfolioStrategy #LifeSciences #Pharma #MarketIntelligence #GoToMarket #EskopeoAdvisors #InsightHealth

𝐄𝐬𝐤𝐨𝐩𝐞𝐨 𝐀𝐝𝐯𝐢𝐬𝐨𝐫𝐬 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬 𝐰𝐢𝐭𝐡 𝐦𝐬𝐠 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐚𝐝𝐯𝐢𝐬𝐨𝐫𝐬 𝐭𝐨 𝐛𝐫𝐢𝐝𝐠𝐞 𝐒𝐓𝐑𝐀𝐓𝐄𝐆𝐘 𝐚𝐧𝐝 𝐄𝐗𝐄𝐂𝐔𝐓𝐈𝐎𝐍 𝐢𝐧 𝐩𝐡𝐚𝐫𝐦𝐚 The biggest challenge in pharma transformation is rarely the strategy itself. It is translating strategic ambition into measurable business impact across portfolios, processes, data, systems and field execution. This is why Eskopeo Advisors is partnering with msg industry advisors ag, a specialized Life Sciences consultancy backed by the global msg and its 10,000+ experts. Together, we combine senior pharma leadership experience, commercial transformation expertise, operating model know-how, and technology-enabled execution capabilities to help pharmaceutical companies unlock value faster. At Eskopeo, we work peer-to-peer with pharma CEOs to identify untapped portfolio potential, uncover hidden growth opportunities, simplify complexity, and improve commercial performance. But successful transformation requires more than a strong business case. Commercial strategy only creates impact when systems, data, processes, and operating models enable the strategy instead of slowing it down. This is where our integrated alliance creates a unique advantage: 📈 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐞𝐝 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐲 Eskopeo defines portfolio priorities, margin opportunities, and commercial ambition, while msg industry advisors translate them into scalable operating models and execution-ready foundations. 🚀 𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞𝐝 𝐆𝐨-𝐭𝐨-𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 Eskopeo redesigns commercial models and local field force setups, while msg industry advisors align processes, CRM, data, and technology capabilities to enable sustainable change. ⚙️ 𝐒𝐢𝐦𝐩𝐥𝐢𝐟𝐢𝐞𝐝 𝐎𝐩𝐞𝐫𝐚𝐭𝐢𝐨𝐧𝐬 & 𝐒𝐲𝐬𝐭𝐞𝐦 𝐄𝐧𝐚𝐛𝐥𝐞𝐦𝐞𝐧𝐭 Together, we remove unnecessary complexity before technology implementation begins, creating leaner, more focused and more effective transformations. Our alliance combines executive-level pharma expertise with strong transformation and execution capabilities. The result: strategies that do not remain on paper but translate into measurable business outcomes. Together with msg industry advisors, we look forward to supporting pharma leaders on their next transformation journey. 👉 Contact us to receive our joint executive brief. 📩 info@eskopeo.com #CommercialExcellence #PharmaTransformation #GoToMarket #DigitalTransformation #GxP

Your sales org chart is probably costing you a fortune! Here's why. We often talk about "omnichannel strategy" as if it’s a cure-all. In reality, it’s often enough just a polite term for organizational bloat. We’ve watched mid-market firms stack field teams, inside sales, CRM specialists, multi-channel managers, and agencies right on top of each other. The intent is synergy. The reality is usually coordination noise: ➡️ The massive time drain: Reps frequently end up spending just ~30% of their week actually facing customers. The other 70% is consumed by internal navigation and admin work (Source: Salesforce State of Sales). ➡️ App overload is real: Navigating up to a dozen software tools daily creates cognitive friction, slowing down pipeline velocity by up to 40% (Source: Gartner / McKinsey). ➡️ The EBITDA leak: When systems remain fragmented, data silos emerge and burn cash – eroding up to 5% of direct EBITDA (Source: EY Research). The root issue isn't a lack of effort or a need for a larger field force. It’s treating new channels as organizational additives rather than structural substitutes. If adding inside sales doesn’t change the footprint of the field force, or if a new CRM doesn't eliminate internal alignment meetings, it’s just building a heavier matrix. When we look at lean commercial engines, the leadership teams usually check themselves against three baseline realities: 1️⃣ The Meeting Ratio: Is customer-facing time actively protected, or is it being crowded out by internal marketing, sales, and medical alignment syncs? 2️⃣ The Tool Friction: If a rep logs into more than 4 applications a week, the business is paying for software navigation, not market execution. 3️⃣ The Clean Sheet: Knowing what the market looks like today, would we build the org chart we currently have? Managing the noise is an endless task; designing it out of the architecture is where the actual upside lives. #CommercialExcellence #GTMStrategy #SalesEnablement #Eskopeo

While you are reading this post, parts of your portfolio may already be losing value. Not because your products are bad. But because resources, focus, and commercial attention are spread too thin. In many drug companies, complexity slowly sneaks in and replaces real strategy. We see it happen all the time: ● Way too many products on the shelves ● Endless busywork that doesn't move the needle ● Legacy projects that nobody has the heart to kill The result isn’t innovation. It’s dilution √ Rising costs and pricing pressure mean the old success model of "breadth at all costs" no longer works. The future doesn’t belong to companies with the largest pipelines. It belongs to those with the clearest focus. The pharmaceutical industry isn’t in crisis – it’s just undergoing a massive makeover √ Real value is no longer created by adding more assets, but by making harder operational decisions: ❶ Double down: Focus entirely on your absolute best, proven projects. ❷ Sort out payors early: Build your pricing and reimbursement plans right from the start! ❸ Pull the plug: Have the guts to stop weak projects the second they start dragging you down. ❹ Recycle: Give your existing products a second life by finding new patient groups or uses for them. Let's be honest – the analysis is the easy part! The real challenge is finding the courage to challenge legacy structures, reallocate resources, and simplify. If you're running a mid-sized company, your "hidden champions" are probably already sitting right there in your portfolio! They are just too well hidden under the weight of historical organizational layers. As an operator, you have to ask yourself: Where is the real magic happening in your portfolio today, and what are you going to stop doing to fund it? #PharmaStrategy #PortfolioOptimization #Pharmaceuticals #Eskopeo #Leadership #ResourceAllocation

Most pharma companies don’t have a strategy problem.  They have a focus problem.  And I’ve seen this from the inside — across 20+ years in leadership roles.    Portfolios full of potential, but:  - too many priorities  - unclear resource allocation  - limited link between decisions and impact    In my last CEO role, we challenged exactly this.  We simplified.  We focused.  We made tough choices.   The result?  A clear turnaround — from loss to profitability.  That experience shaped a conviction:   👉 Most portfolios can deliver significantly more than they currently do.  That’s why we built Eskopeo Advisors.  A structured, pragmatic way to identify and unlock the value already there.    No theory.  No noise.  Just impact.    If you feel your portfolio is underperforming its potential — let’s talk.    #pharma #leadership #strategy #valuecreation #growth 

Pharma CEOs: Is your organization working harder, but standing still? In mid-sized pharma, growth often gets buried under "historically grown" layers—SKUs that no longer serve the mission and commercial models that outpace market reality. At Eskopeo Advisors, we believe sustainable performance doesn’t come from working harder – Performance is expected; Clarity is what is missing. We use our P-I-V Engine (Purpose-Impact-Value) to audit portfolios and unlock hidden value that is quietly draining your EBITDA. Our "High Insight, Low Risk" approach means we only move forward if the upside is proven. Visit our website to see how we bridge the gap between clinical potential and commercial success. #PharmaStrategy #LifeSciences #ExecutiveLeadership #EBITDA #EskopeoAdvisors